Effect of pegylated phosphatidylserine-containing liposomes in experimental chronic arthritis.

Autor: Urbano PC; Biotechnology and Bioprocess Engineering, Universidade Federal do Paraná, Curitiba, Paraná, Brazil. pc_ibc@yahoo.com.br., Soccol VT; Biotechnology and Bioprocess Engineering, Universidade Federal do Paraná, Curitiba, Paraná, Brazil. vanetesoccol@gmail.com., Teixeira VN; Rheumatology Department, Hospital de Clínicas de Porto Alegre (HCPA), Rio Grande do Sul, Brazil. viviont@gmail.com., Oliveira PG; Rheumatology Department, Hospital de Clínicas de Porto Alegre (HCPA), Rio Grande do Sul, Brazil. patty.go@gmail.com., Filippin LI; Rheumatology Department, Hospital de Clínicas de Porto Alegre (HCPA), Rio Grande do Sul, Brazil. lidifilippin@gmail.com., Bonat WH; Statistical Laboratory (LABEST), Universidade Federal do Paraná (UFPR), Curitiba, Paraná, Brazil. wbonat@gmail.com., de Oliveira C; Department of Cell Biology, Research Laboratory of Inflammatory Cells and Neoplastic, Universidade Federal do Paraná (UFPR), Curitiba, Paraná, Brazil. krokoli@hotmail.com., Rossi GR; Department of Cell Biology, Research Laboratory of Inflammatory Cells and Neoplastic, Universidade Federal do Paraná (UFPR), Curitiba, Paraná, Brazil. gustavo.r.rossi@hotmail.com., Xavier RM; Rheumatology Department, Hospital de Clínicas de Porto Alegre (HCPA), Rio Grande do Sul, Brazil. rxavier10@gmail.com., Azevedo VF; Rheumatology Service and Internal Medicine, Hospital de Clínicas de Curitiba, Universidade Federal do Paraná (UFPR), Rua Alvaro Alvin, 224 casa 18, Curitiba, Paraná, 80440080, Brazil. Valderilio@hotmail.com.
Jazyk: angličtina
Zdroj: BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2015 Sep 22; Vol. 16, pp. 24. Date of Electronic Publication: 2015 Sep 22.
DOI: 10.1186/s40360-015-0022-0
Abstrakt: Background: Phosphatidylserine-containing liposomes (PSL) have been shown to reduce inflammation in experimental models of acute arthritis, by mimicking the apoptotic process. The aim of this study was to evaluate the effect of pegylated PSL (PEG-PSL) on chronic inflammation of collagen induced arthritis (CIA) in DBA/1J mice.
Methods: CIA was induced in 24 DBA/1J mice (n = 6/group), which were divided into control (0.9 % saline) or treated with PEG-PSL (5, 10 and 15 mg/kg/day, subcutaneously for 20 days). Clinical score, limb histology and measurement of cytokines in knee joints of animals by ELISA and cytometric bead array (CBA) were evaluated. The in vitro study employed macrophage cultures stimulated with 100 ng/ml of LPS plus 10 ng/ml of PMA and treated with 100 μM PEG-PSL.
Results: Resolution of the disease in vivo and the inflammatory process in vitro were not observed. PEG-PSL, in doses of 10 and 15 mg/kg, were not shown to reduce the score of the disease in animals, whereas with the dose of 5 mg/kg, the animals did not show the advanced stage of the disease when compared to the controls. The PEG- PSL 5, 10 and 15 mg/kg treatment groups did not show significant reduction of TNF-α, IL-1β, IL-6, IL-2 and IFN-γ when compared to the controls. Disease incidence and animal weights were not affected by treatment. Regarding the paw histology, PEG-PSL did not yield any reductions in the infiltrating mononuclear, synovial hyperplasia, extension of pannus formation, synovial fibrosis, erosion of cartilage, bone erosion or cartilage degradation. The concentration of 100 μM of PEG-PSL has not been shown to reduce inflammation induced by LPS/PMA in the in vitro study. Treated groups did not show any reduction in inflammatory cytokines in the knee joints of animals affected by the disease compared to the control, although there were higher concentrations of TGF-β1 in all experimental groups.
Conclusion: The experimental model showed an expression of severe arthritis after the booster. TGF-β1 as well other pro inflammatory cytokines were presented in high concentrations in all groups. PEG-PSL had no impact on the clinical score, the histopathology from tibial-tarsal joints or the production of cytokines in the knee joints. Other alternatives such as dosage, route of administration, and as an adjunct to a drug already on the market, should be evaluated to support the use of PEG-PSL as a new therapeutic tool in inflammatory diseases.
Databáze: MEDLINE
Externí odkaz: